Showing results (61-70 of 171) with videos related to
Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|September 7, 2010
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicityGeoffrey Y Ku, Akhil Chopra, Gilberto de Lima LopesAnnals of Surgical Oncology|December 28, 2013
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancersDo Joong Park, Changhwan Yoon, Nicholas Thomas, et al.Current Treatment Options in Oncology|May 10, 2014
HER2 directed therapy for gastric/esophageal cancersElizabeth Won, Yelena J Janjigian, David H IlsonSeminars in Oncology|August 7, 2004
Treatment of localized esophageal cancerBaruch Brenner, David H Ilson, Bruce D MinskyAsia-Pacific Journal of Clinical Oncology|May 19, 2011
Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case seriesGeoffrey Y Ku, Gilberto De Lima Lopes, Alex Y ChangLung Cancer (Amsterdam, Netherlands)|May 14, 2011
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trialsGeoffrey Y Ku, Benjamin A Haaland, Gilberto de Lima LopesCancer Chemotherapy and Pharmacology|June 16, 2012
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine mattersGeoffrey Y Ku, Benjamin A Haaland, Gilberto de Lima LopesThe Oncologist|September 24, 2005
Targeted therapies for esophageal cancerWilliam P Tew, David P Kelsen, David H IlsonCancer Investigation|October 10, 2003
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancerSibyl E Anderson, Eileen M O'Reilly, David P Kelsen, et al.The British Journal of Surgery|December 16, 2025
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort studyMasaya Nakauchi, Colin Court, Henry S Walch, et al.Pageof 18